Vancomycin PO

C difficile risk
Oral Bioavailability

Spectrum Of Activity


125mg po/ng/og q6h for 10-14 days.

Intra-colonic dose 500mg in 100mL of NS by rectal enema q6h

General Information

Antimicrobial Stewardship approved criteria must be indicated at ORDER ENTRY.

Approved Indications:

  1. PRE-OP Dose
  2. Bacteremia [Severe]
  3. Endocarditis [Severe]
  4. Meningitis, Community-onset [Severe]
  5. Meningitis, Hospital-onset [Severe]
  6. Neutropenic fever [Severe]
  7. Osteomyelitis [Severe]
  8. Pneumonia [Severe]
  9. Sepsis (e.g. qSOFA >2) [Severe]
  10. SSTI –Necrotizing fasciitis [Severe]
  11. SSTI –Comp cellulitis/abscess [Moderate]
  12. SSTI –Uncomp cellulitis/abscess [Mild]
  13. Urinary tract infection [Mild]
  14. Clostridium difficile

Only indication is in the therapy of C. difficile infection, particularly recurrent or severe disease

Possibility of accumulation in severe renal dysfunction.

Consider checking a vancomycin level in dialysis patients.

No oral absorption.

May increase vancomycin resistant Enterococci colonization in the gut.

Antimicrobial class: Glycopeptide

Pregnancy category: B

Average serum half life: 0 hours

Biliary penetration: None

CSF penetration: None

Lung penetration: None

Urine penetration: None